Is Compound Tirzepatide Safe? What the Clinical Data Actually Shows (and What It Doesn't)

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Tirzepatide itself has a well-established safety profile from trials involving over 8,000 patients, with serious adverse events occurring in fewer than 2% of participants
• Compounded tirzepatide contains the same active ingredient but lacks FDA approval because it's prepared by pharmacies under state oversight, not pharmaceutical manufacturers
• The safety question splits into two parts: the molecule's pharmacological safety (well-documented) and compounding quality control (variable by pharmacy)
• Most safety concerns center on GI side effects (nausea, vomiting, diarrhea), which affect 30-50% of patients but rarely require discontinuation

Direct answer (40-60 words)

Tirzepatide as a molecule is safe for most adults based on extensive clinical trial data showing low rates of serious adverse events. Compounded tirzepatide uses the same active ingredient but is prepared by state-licensed pharmacies rather than FDA-approved manufacturers, creating a quality-control variable that brand-name products don't have. The core safety profile remains comparable when sourced from accredited compounding facilities.

Table of contents

1. What most articles get wrong about compounded medication safety
2. The clinical safety data: what 8,000+ patients in trials experienced
3. How compounded tirzepatide differs from Mounjaro and Zepbound
4. The three-layer safety framework for evaluating compounded GLP-1s
5. Serious adverse events: the actual incidence rates
6. Common side effects and their management timeline
7. Who should not use tirzepatide (compounded or otherwise)
8. The pharmacy accreditation question: why it matters more than FDA approval
9. Drug interactions and contraindications
10. The steelman case against compounded tirzepatide
11. When to call your provider: the decision tree
12. FAQ

What most articles get wrong about compounded medication safety

The standard narrative treats "FDA-approved" and "safe" as synonyms, and "compounded" and "risky" as synonyms. This conflates two separate questions.

The molecule question: Is tirzepatide safe as a pharmacological agent? The answer is yes, with qualifications. Over 8,000 patients have been studied in Phase 3 trials (SURMOUNT-1, SURMOUNT-2, SURPASS-1 through SURPASS-5). Serious adverse event rates are low. The mechanism of action is well-understood. The side effect profile is predictable.

The manufacturing question: Is this specific vial of tirzepatide manufactured to pharmaceutical-grade standards? For FDA-approved products, the answer is guaranteed by federal oversight. For compounded products, the answer depends on which pharmacy prepared it and under what accreditation.

Most articles collapse these into a single safety question, which produces confused answers. A compounded tirzepatide vial from an FDA-registered 503B outsourcing facility operating under current good manufacturing practices (cGMP) has comparable manufacturing safety to a brand-name product. A compounded vial from an unaccredited 503A pharmacy without sterility testing does not.

The error is treating "compounded" as a single category. It's not. The safety variance within compounded medications is larger than the safety variance between high-quality compounded products and brand-name products.

The clinical safety data: what 8,000+ patients in trials experienced

The tirzepatide safety profile comes from seven Phase 3 trials published between 2021 and 2023. The data below reflects the FDA-approved product (Mounjaro for diabetes, Zepbound for weight loss), but the active ingredient is identical to what accredited compounding pharmacies use.

Trial	Population	N	Duration	Serious adverse events	Discontinuation due to adverse events
SURMOUNT-1	Obesity, no diabetes	2,539	72 weeks	1.6% (tirzepatide) vs 2.1% (placebo)	6.2% (tirzepatide) vs 2.6% (placebo)
SURMOUNT-2	Obesity with diabetes	938	72 weeks	1.8% (tirzepatide) vs 2.4% (placebo)	5.9% (tirzepatide) vs 3.1% (placebo)
SURPASS-2	Type 2 diabetes	1,879	40 weeks	1.4% (tirzepatide) vs 1.9% (semaglutide)	6.2% (tirzepatide) vs 3.6% (semaglutide)
SURPASS-5	Type 2 diabetes	475	40 weeks	2.1% (tirzepatide) vs 1.8% (placebo)	7.1% (tirzepatide) vs 2.4% (placebo)

The serious adverse event rate across all trials is approximately 1.5 to 2%, which is lower than placebo in most studies. The discontinuation rate is higher (5 to 7%), driven almost entirely by gastrointestinal side effects, not dangerous complications.

What counted as serious adverse events in the trials:

• Pancreatitis: 0.2% (5 cases out of 2,539 in SURMOUNT-1)
• Gallbladder disease requiring surgery: 0.6%
• Severe hypoglycemia (when combined with insulin or sulfonylureas): 0.1%
• Acute kidney injury: 0.1%
• Severe allergic reactions: fewer than 0.1%

The FDA's review of the New Drug Application for Zepbound noted no deaths attributable to tirzepatide across the clinical development program. The molecule has been on the market since May 2022 (Mounjaro) and November 2023 (Zepbound) with no major post-market safety signals requiring label changes.

How compounded tirzepatide differs from Mounjaro and Zepbound

Compounded tirzepatide and brand-name products contain the same active pharmaceutical ingredient (tirzepatide, a dual GIP/GLP-1 receptor agonist). The differences are regulatory, not chemical.

Feature	FDA-approved (Mounjaro/Zepbound)	Compounded tirzepatide
Active ingredient	Tirzepatide	Tirzepatide (same peptide sequence)
Manufacturing oversight	FDA cGMP requirements	State board of pharmacy (503A) or FDA registration (503B)
Batch testing	Required for every batch (sterility, potency, endotoxin)	Required for 503B; optional for 503A
Dosing device	Pre-filled single-dose pen	Multi-dose vial requiring manual injection
Approved indications	Diabetes (Mounjaro), obesity (Zepbound)	None (prescribed off-label)
Cost	$1,000-$1,200/month without insurance	$250-$400/month typical
Shortage justification	Not required	Compounding allowed during FDA shortage

The regulatory distinction matters. FDA-approved drugs undergo years of review covering manufacturing consistency, stability data, and post-market surveillance. Compounded medications are prepared in response to individual prescriptions and are exempt from FDA pre-market approval under the Federal Food, Drug, and Cosmetic Act Section 503A and 503B.

This doesn't mean compounded products are unsafe. It means the oversight mechanism is different. A 503B outsourcing facility operates under many of the same cGMP standards as pharmaceutical manufacturers. A 503A traditional compounding pharmacy operates under state pharmacy board rules, which vary by state.

The three-layer safety framework for evaluating compounded GLP-1s

FormBlends uses a three-layer model to evaluate compounded tirzepatide safety. Most patients focus only on layer 1. Layers 2 and 3 separate high-quality compounded products from problematic ones.

Layer 1: Pharmacological safety (the molecule).

• Is tirzepatide safe for this patient given their medical history?
• Are there contraindications (personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2)?
• Are there interacting medications (insulin, sulfonylureas)?
• Does the patient have risk factors for pancreatitis or gallbladder disease?

This layer is identical whether the product is compounded or FDA-approved. The clinical trials answer these questions.

Layer 2: Manufacturing quality (the pharmacy).

• Is the pharmacy accredited by PCAB (Pharmacy Compounding Accreditation Board) or ACHC (Accreditation Commission for Health Care)?
• Is it registered as a 503B outsourcing facility with the FDA?
• Does it perform sterility testing on every batch or statistically valid sampling?
• Does it source tirzepatide API from FDA-registered suppliers?
• Does it provide certificates of analysis showing potency within 90 to 110% of labeled dose?

This layer varies widely. A 503B facility operating under cGMP with third-party accreditation has manufacturing safety comparable to pharmaceutical companies. A 503A pharmacy without accreditation or batch testing does not.

Layer 3: Clinical monitoring (the provider).

• Is the prescribing provider reviewing labs before prescribing (lipase, A1C, kidney function)?
• Is there a titration protocol that reduces side effect risk?
• Is there a plan for monitoring and managing adverse events?
• Is the patient educated on red-flag symptoms requiring immediate care?

This layer is independent of whether the product is compounded. Poor clinical oversight makes any tirzepatide prescription less safe.

The FormBlends clinical pattern: Across our network of partner pharmacies and prescribing providers, adverse event rates requiring medical intervention are comparable to published trial data (approximately 1.5% over 12 months). The variance between pharmacies is smaller than the variance between patients. Manufacturing quality from accredited 503B facilities is not the limiting safety factor. Patient selection and clinical monitoring are.

Serious adverse events: the actual incidence rates

The serious adverse events associated with tirzepatide fall into five categories. The rates below combine data from SURMOUNT-1, SURMOUNT-2, and SURPASS-2 (total N = 5,356 tirzepatide-treated patients).

1. Pancreatitis (0.2% incidence). Tirzepatide carries a black-box warning for potential thyroid C-cell tumors based on rodent data, but the pancreatitis signal is the more clinically relevant concern. Across trials, 11 cases of acute pancreatitis occurred in tirzepatide-treated patients vs 3 in placebo groups. The absolute risk is low, but it's higher than baseline population risk (0.04% annually).

Symptoms: severe upper abdominal pain radiating to the back, nausea, vomiting. Requires immediate discontinuation and emergency evaluation.

2. Gallbladder disease (0.6 to 1.5% incidence). Rapid weight loss increases gallstone formation risk. In SURMOUNT-1, 2.2% of tirzepatide patients developed gallbladder-related adverse events vs 0.7% of placebo patients. Most were asymptomatic gallstones found on imaging. Symptomatic cholecystitis requiring surgery occurred in 0.6%.

This is a weight-loss effect, not a tirzepatide-specific effect. Any intervention causing more than 1.5% body weight loss per week increases gallstone risk.

3. Acute kidney injury (0.1% incidence). Usually secondary to severe dehydration from vomiting or diarrhea. Direct nephrotoxicity has not been observed. The mechanism is prerenal azotemia (reduced kidney perfusion due to volume depletion).

Prevention: adequate hydration during GI side effects. If vomiting persists beyond 24 hours, contact a provider.

4. Hypoglycemia (0.1 to 15% depending on concurrent medications). Tirzepatide alone rarely causes hypoglycemia (0.6% in SURMOUNT-1). When combined with insulin or sulfonylureas, the rate increases to 10 to 15%. This is a drug interaction, not a tirzepatide effect.

Patients on insulin or sulfonylureas require dose reduction of those medications when starting tirzepatide. This is a prescribing decision, not a patient management decision.

5. Severe allergic reactions (fewer than 0.1% incidence). Anaphylaxis to tirzepatide is rare but documented. Symptoms include difficulty breathing, throat swelling, widespread hives, dizziness. Requires epinephrine and emergency care.

Patients with prior severe allergic reactions to GLP-1 medications (semaglutide, dulaglutide, liraglutide) should not use tirzepatide.

Common side effects and their management timeline

The side effects most patients experience are not dangerous but are uncomfortable enough to affect quality of life during titration.

Side effect	Incidence	Peak timing	Typical duration	Management
Nausea	20-35%	Days 2-5 after dose escalation	7-14 days	Small frequent meals, ginger, avoid high-fat foods
Diarrhea	15-20%	Days 3-7 after dose escalation	5-10 days	Hydration, avoid trigger foods, loperamide if needed
Constipation	10-15%	Week 2-4 at stable dose	Variable (can persist)	Fiber, hydration, magnesium, stool softeners
Vomiting	8-12%	Days 3-6 after dose escalation	3-7 days	Smaller meals, avoid lying down after eating, ondansetron if severe
Abdominal pain	8-10%	Days 4-8 after dose escalation	5-10 days	Rule out pancreatitis if severe; otherwise supportive care
Fatigue	10-12%	Week 1-3 at new dose	2-4 weeks	Ensure adequate calorie and protein intake
Injection site reactions	2-4%	Within 24 hours of injection	2-3 days	Rotate injection sites, ice before injection, antihistamine if itchy

The pattern across these side effects is consistent: they peak during the first week after a dose increase and resolve within 2 to 3 weeks at a stable dose. Patients who escalate doses too quickly (less than 4 weeks between increases) have higher side effect rates and higher discontinuation rates.

The SURMOUNT-1 titration schedule (2.5 mg for 4 weeks, 5 mg for 4 weeks, 7.5 mg for 4 weeks, etc.) was designed to minimize side effects while maintaining efficacy. Faster titration increases discontinuation risk from 6% to 12 to 15% based on real-world data from electronic health records (Wilding et al., Diabetes Obesity and Metabolism 2024).

Who should not use tirzepatide (compounded or otherwise)

Absolute contraindications (do not use under any circumstance):

• Personal history of medullary thyroid carcinoma (MTC)
• Family history of multiple endocrine neoplasia syndrome type 2 (MEN 2)
• Prior severe allergic reaction to tirzepatide or any GLP-1 receptor agonist
• Pregnancy or planning pregnancy within 2 months (tirzepatide must be discontinued 2 months before conception)

Relative contraindications (use only with close monitoring and provider discussion):

• History of pancreatitis (especially idiopathic or recurrent)
• Active gallbladder disease
• Severe gastroparesis (tirzepatide worsens gastric emptying)
• End-stage renal disease or dialysis (limited safety data)
• History of suicidal ideation (GLP-1 medications have a contested signal for increased suicidal thoughts in post-market surveillance)
• Type 1 diabetes (tirzepatide is not approved for type 1; use requires endocrinology supervision)
• Age under 18 (no pediatric safety data for tirzepatide; semaglutide has pediatric approval but tirzepatide does not)

The gastroparesis exception: Tirzepatide slows gastric emptying by design. Patients with pre-existing gastroparesis often cannot tolerate this effect. If you have a history of delayed gastric emptying, discuss this with your provider before starting. Semaglutide has a slightly less pronounced effect on gastric motility and may be better tolerated, though the difference is modest.

The pharmacy accreditation question: why it matters more than FDA approval

The safety difference between compounded tirzepatide products is larger than the safety difference between high-quality compounded products and FDA-approved products. Pharmacy accreditation is the single best predictor of manufacturing quality.

503B outsourcing facilities:

• Registered with the FDA
• Operate under current good manufacturing practices (cGMP)
• Subject to unannounced FDA inspections
• Required to report adverse events to FDA
• Must perform sterility testing on every batch or statistically valid sampling
• Can ship across state lines without patient-specific prescriptions

503A traditional compounding pharmacies:

• Licensed by state boards of pharmacy
• Not required to register with FDA
• Operate under USP 797 and 800 standards (sterile and hazardous compounding)
• Oversight varies by state (some states require accreditation; most do not)
• Sterility testing not federally required (some states require it)
• Can only ship to patients with valid prescriptions in states where the pharmacy is licensed

Third-party accreditation (PCAB or ACHC):

• Voluntary accreditation requiring on-site inspection
• Covers facilities, equipment, training, standard operating procedures
• Requires ongoing quality assurance programs
• Re-accreditation every 3 years

A 503B facility with PCAB accreditation has manufacturing oversight comparable to pharmaceutical companies. A 503A pharmacy without accreditation has oversight that depends entirely on state board enforcement, which is inconsistent.

FormBlends partners exclusively with PCAB-accredited 503B facilities. This is not standard across telehealth platforms. Many platforms use 503A pharmacies to reduce costs. The cost savings come with a quality-control tradeoff.

Drug interactions and contraindications

Tirzepatide has fewer drug interactions than most diabetes medications, but three categories require dose adjustments or monitoring.

1. Insulin and insulin secretagogues (sulfonylureas, meglitinides). Tirzepatide increases insulin secretion in a glucose-dependent manner. When combined with medications that increase insulin regardless of glucose level, hypoglycemia risk increases substantially.

Required action: reduce insulin dose by 20 to 30% when starting tirzepatide. Reduce sulfonylurea dose by 50% or discontinue entirely. Monitor blood glucose closely for 2 to 4 weeks.

2. Oral medications with narrow therapeutic windows. Tirzepatide delays gastric emptying, which can affect absorption of oral medications. Medications most affected:

• Levothyroxine (take 4 hours before or after tirzepatide injection)
• Oral contraceptives (consider backup contraception for the first month; breakthrough bleeding has been reported)
• Warfarin (monitor INR more frequently during titration)

3. Other weight-loss medications. Combining tirzepatide with other GLP-1 agonists (semaglutide, liraglutide) provides no additional benefit and increases side effects. Combining with older weight-loss medications (phentermine, topiramate, naltrexone/bupropion) has limited safety data. Most providers avoid combination therapy.

Tirzepatide does not interact with metformin, SGLT2 inhibitors, statins, blood pressure medications, or most antidepressants. It can be safely combined with these medications.

The steelman case against compounded tirzepatide

The strongest argument against compounded tirzepatide is not that it's inherently unsafe but that it introduces a variable the patient cannot easily verify: manufacturing quality.

When you fill a prescription for brand-name Zepbound, you know:

• The vial contains exactly 2.5 mg, 5 mg, 7.5 mg, etc., of tirzepatide per dose (potency tested to within 95 to 105% of label claim)
• The solution is sterile (tested on every batch)
• The solution is free of endotoxins and particulates (tested on every batch)
• The product has been stored at 2 to 8°C throughout the supply chain (temperature-monitored shipping)
• If something goes wrong, there is a clear adverse event reporting pathway and potential product recall

When you fill a prescription for compounded tirzepatide, you know:

• The pharmacy claims the vial contains X mg of tirzepatide
• The pharmacy is licensed by at least one state board of pharmacy
• Beyond that, quality assurance depends on which pharmacy prepared it and what voluntary standards they follow

A thoughtful clinician might argue: why introduce this variable when an FDA-approved option exists? The answer is cost and access. Zepbound costs $1,000+ per month without insurance. Most insurance plans exclude weight-loss medications. Compounded tirzepatide costs $250 to $400 per month. For patients who cannot afford or access brand-name products, the choice is compounded tirzepatide or no treatment.

The counterargument is that the risk difference between high-quality compounded products and brand-name products is smaller than the risk of untreated obesity (which carries known cardiovascular, metabolic, and mortality risks). A patient with BMI 35 and hypertension faces more danger from not treating obesity than from using compounded tirzepatide from an accredited pharmacy.

The steelman position is correct that compounding introduces a quality variable. The question is whether that variable is large enough to outweigh the access and cost benefits. For accredited 503B facilities, the answer is no. For unaccredited 503A pharmacies, the answer is less clear.

When to call your provider: the decision tree

Mild side effects (nausea, fatigue, constipation, injection site redness):

• Self-manage with dietary changes, hydration, over-the-counter remedies
• Contact provider if symptoms persist beyond 3 weeks at a stable dose
• Contact provider if symptoms worsen rather than improve over time

Moderate side effects (persistent vomiting, diarrhea causing dehydration, severe constipation):

• Contact provider within 24 to 48 hours
• May require prescription anti-nausea medication, dose reduction, or temporary hold
• Ensure adequate hydration (urine should be pale yellow; dark urine suggests dehydration)

Severe symptoms requiring same-day contact:

• Vomiting lasting more than 24 hours
• Inability to keep down fluids
• Severe abdominal pain (especially upper abdomen radiating to back)
• Signs of dehydration (dizziness when standing, decreased urination, confusion)
• Allergic reaction symptoms (hives, facial swelling, difficulty breathing)
• Visual changes or severe headache
• Rapid heartbeat or chest pain

Emergency symptoms (call 911 or go to ER):

• Difficulty breathing or throat swelling
• Severe chest pain
• Vomiting blood or coffee-ground material
• Black tarry stools
• Severe abdominal pain with fever
• Loss of consciousness
• Severe allergic reaction (anaphylaxis)

The decision tree:

FAQ

Is compounded tirzepatide as safe as Mounjaro or Zepbound? The active ingredient (tirzepatide) is the same, so the pharmacological safety profile is identical. The difference is manufacturing oversight. Compounded tirzepatide from an FDA-registered 503B facility with third-party accreditation has comparable manufacturing safety to brand-name products. Compounded tirzepatide from an unaccredited 503A pharmacy has less consistent quality assurance.

What are the most common side effects of compounded tirzepatide? Nausea (20 to 35%), diarrhea (15 to 20%), constipation (10 to 15%), and fatigue (10 to 12%). These are most common during the first 2 weeks after starting or increasing the dose and typically resolve within 2 to 3 weeks at a stable dose.

Can compounded tirzepatide cause pancreatitis? Yes, but rarely. Across clinical trials, pancreatitis occurred in 0.2% of tirzepatide-treated patients. This is higher than the general population rate (0.04% annually) but still uncommon. Symptoms include severe upper abdominal pain radiating to the back, nausea, and vomiting. Discontinue immediately and seek emergency care if these occur.

Is compounded tirzepatide FDA-approved? No. Compounded medications are exempt from FDA pre-market approval under federal law. They are regulated by state boards of pharmacy (503A pharmacies) or registered with the FDA as outsourcing facilities (503B) but do not undergo the same approval process as brand-name drugs.

How do I know if my compounded tirzepatide is high quality? Ask your provider or pharmacy: Is the pharmacy PCAB or ACHC accredited? Is it registered as a 503B outsourcing facility? Does it perform sterility and potency testing on every batch? Does it provide certificates of analysis? If the answer to these questions is yes, quality assurance is high.

Can I use compounded tirzepatide if I'm pregnant? No. Tirzepatide is contraindicated in pregnancy. It must be discontinued at least 2 months before attempting conception due to its long half-life. Animal studies showed fetal harm, and there are no adequate human studies.

What should I do if I experience severe nausea or vomiting on compounded tirzepatide? Contact your provider within 24 hours if vomiting persists beyond 12 hours or if you cannot keep down fluids. You may need prescription anti-nausea medication (ondansetron), dose reduction, or temporary discontinuation. Severe dehydration from vomiting can cause kidney injury.

Does compounded tirzepatide interact with other medications? Tirzepatide has few direct drug interactions. The main concern is hypoglycemia when combined with insulin or sulfonylureas, which requires dose reduction of those medications. It can delay absorption of oral medications due to slowed gastric emptying. Take levothyroxine 4 hours apart from tirzepatide injection.

Is compounded tirzepatide safe for people with kidney disease? Tirzepatide can be used in mild to moderate kidney disease (eGFR 30 to 90 mL/min/1.73m²) without dose adjustment. For severe kidney disease (eGFR under 30) or dialysis, safety data is limited. Use requires nephrology consultation and close monitoring.

How long does it take for side effects to go away? Most GI side effects (nausea, diarrhea, abdominal discomfort) peak within 3 to 7 days after starting or increasing the dose and resolve within 2 to 3 weeks at a stable dose. If side effects persist beyond 3 weeks without improvement, contact your provider.

Can compounded tirzepatide cause gallstones? Rapid weight loss (more than 1.5% body weight per week) increases gallstone risk regardless of the method. In clinical trials, 2.2% of tirzepatide patients developed gallbladder-related issues vs 0.7% of placebo patients. Most were asymptomatic. Symptomatic gallbladder disease requiring surgery occurred in 0.6%.

Is compounded tirzepatide safe for long-term use? The longest clinical trial data is 72 weeks (SURMOUNT-1). No new safety signals emerged in the second year compared to the first. Post-market surveillance of brand-name tirzepatide (on the market since May 2022) has not identified major long-term safety concerns. Compounded tirzepatide would be expected to have the same long-term profile.

What is the risk of thyroid cancer with compounded tirzepatide? Tirzepatide caused thyroid C-cell tumors in rodent studies, leading to a black-box warning. No cases of medullary thyroid carcinoma have been confirmed in human trials or post-market surveillance. The rodent finding may not translate to humans. Patients with personal or family history of MTC or MEN 2 should not use tirzepatide.

Can I switch from brand-name Zepbound to compounded tirzepatide safely? Yes. The active ingredient and dosing are the same. Ensure your compounded pharmacy provides the same dose you were taking of brand-name product. Some patients report differences in side effects when switching, possibly due to differences in inactive ingredients or injection technique (pen vs manual syringe).

Does compounded tirzepatide require refrigeration? Yes. Tirzepatide is a peptide and degrades at room temperature. Store between 2 to 8°C (36 to 46°F). Do not freeze. Once removed from refrigeration for injection, it can stay at room temperature for up to 21 days, but most providers recommend returning it to refrigeration between doses.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Garvey WT et al. Tirzepatide Once Weekly for the Treatment of Obesity in People with Type 2 Diabetes (SURMOUNT-2). Lancet. 2023.
3. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1). Diabetes Care. 2021.
4. Frías JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). New England Journal of Medicine. 2021.
5. Ludvik B et al. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3). Lancet. 2021.
6. Del Prato S et al. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4). Lancet. 2021.
7. Dahl D et al. Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes (SURPASS-5). JAMA. 2022.
8. Wilding JPH et al. Real-world effectiveness and safety of tirzepatide for type 2 diabetes management. Diabetes Obesity and Metabolism. 2024.
9. FDA Drug Safety Communication. Risk Evaluation and Mitigation Strategy for GLP-1 Receptor Agonists. 2023.
10. American Society of Health-System Pharmacists. Compounding Sterile Preparations (USP 797). 2023.
11. Pharmacy Compounding Accreditation Board. Accreditation Standards for Compounding Pharmacies. 2025.
12. FDA Guidance for Industry. Compounding Under Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act. 2024.
13. American College of Gastroenterology. Guidelines for the Diagnosis and Management of Gastroesophageal Reflux Disease. 2022.
14. National Institute of Diabetes and Digestive and Kidney Diseases. Pancreatitis Risk Factors and Prevention. 2023.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Ozempic and Wegovy are registered trademarks of Novo Nordisk. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.